{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:25:59Z","timestamp":1777375559219,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01301-2","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:37:04Z","timestamp":1747121824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and Management of Genetic Lipodystrophy Syndromes and its Implications for Atherosclerosis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-7018","authenticated-orcid":false,"given":"Josivan Gomes","family":"Lima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-2496","authenticated-orcid":false,"given":"Izabely Galvao Menezes","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2863-2716","authenticated-orcid":false,"given":"Lucas Nobrega","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"1301_CR1","doi-asserted-by":"crossref","unstructured":"Chiquette E, Oral EA, Garg A, Araujo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;375\u201383.","DOI":"10.2147\/DMSO.S130810"},{"key":"1301_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/db19-0447","volume":"69","author":"C Gonzaga-Jauregui","year":"2020","unstructured":"Gonzaga-Jauregui C, Ge W, Staples J, Van Hout C, Yadav A, Colonie R, et al. Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort. Diabetes. 2020;69:249\u201358.","journal-title":"Diabetes"},{"key":"1301_CR3","doi-asserted-by":"crossref","unstructured":"Akinci B, von Schnurbein J, Araujo-Vilar D, Wabitsch M, Oral EA, Lipodystrophy, Prevalence. Lipodystrophy-Like phenotypes, and diagnostic challenges. Diabetes. American Diabetes Association Inc.; 2024. pp. 1039\u201342.","DOI":"10.2337\/dbi24-0018"},{"key":"1301_CR4","doi-asserted-by":"crossref","unstructured":"Costa DG, Ferreira-Marques M, Cavadas C. Lipodystrophy as a target to delay premature aging. Trends in endocrinology and metabolism. Elsevier Inc.; 2024. pp. 97\u2013106.","DOI":"10.1016\/j.tem.2023.10.006"},{"key":"1301_CR5","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1161\/ATVBAHA.113.301933","volume":"33","author":"G Bidault","year":"2013","unstructured":"Bidault G, Garcia M, Vantyghem MC, Ducluzeau PH, Morichon R, Thiyagarajah K, et al. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013;33:2162\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1301_CR6","doi-asserted-by":"crossref","unstructured":"Mosbah H, Vatier C, Boccara F, J\u00e9ru I, Lascols O, Vantyghem MC et al. Looking at new unexpected disease targets in LMNA-Linked lipodystrophies in the light of complex cardiovascular phenotypes: implications for clinical practice. Cells. 2020;9.","DOI":"10.3390\/cells9030765"},{"key":"1301_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5543\/tkda.2023.35893","volume":"52","author":"FE Olgun","year":"2024","unstructured":"Olgun FE, G\u00fcler E, \u00c7ele\u011fen MF, Demir\u00e7elik MB, K\u0131l\u0131\u00e7aslan F, Boztosun B. Early atherosclerosis and conduction defect in a rare case of Dunnigan type Familial partial lipodystrophy. Turk Kardiyoloji Dernegi Arsivi. 2024;52:138\u201342.","journal-title":"Turk Kardiyoloji Dernegi Arsivi"},{"key":"1301_CR8","doi-asserted-by":"crossref","unstructured":"Van Maldergem L, Magre J, Khallouf TE, Gedde-Dahl T Jr., Delepine M, Trygstad O et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002\/10\/04. 2002;39:722\u201333.","DOI":"10.1136\/jmg.39.10.722"},{"key":"1301_CR9","doi-asserted-by":"crossref","unstructured":"Lima JG, Nobrega LHC, Lima NN, dos Santos MCF, Silva PHD, Maria de Fatima PB et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS ONE. 2018;13.","DOI":"10.1371\/journal.pone.0199052"},{"key":"1301_CR10","doi-asserted-by":"crossref","unstructured":"Feij\u00f3 BMXCRR, Mendon\u00e7a RM, Egito EST, Lima DN, Campos JTA, de Lima M. JG. Coronary arterial calcification in patients with congenital generalised lipodystrophy: A case series. Clin Endocrinol (Oxf). John Wiley and Sons Inc; 2022. pp. 863\u20136.","DOI":"10.1111\/cen.14800"},{"key":"1301_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.diabet.2018.09.006","volume":"45","author":"M Kwapich","year":"2019","unstructured":"Kwapich M, Lacroix D, Espiard S, Ninni S, Brigadeau F, Kouakam C, et al. Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype\u2013genotype correlation. Diabetes Metab. 2019;45:382\u20139.","journal-title":"Diabetes Metab"},{"key":"1301_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12020-016-1002-x","volume":"54","author":"C Guill\u00edn-Amarelle","year":"2016","unstructured":"Guill\u00edn-Amarelle C, S\u00e1nchez-Iglesias S, Castro-Pais A, Rodriguez-Ca\u00f1ete L, Ord\u00f3\u00f1ez-May\u00e1n L, Pazos M, et al. Type 1 Familial partial lipodystrophy: Understanding the K\u00f6bberling syndrome. Endocrine. 2016;54:411\u201321.","journal-title":"Endocrine"},{"key":"1301_CR13","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1210\/clinem\/dgad063","volume":"108","author":"SC Adiyaman","year":"2023","unstructured":"Adiyaman SC, Altay C, Kamisli BY, Avci ER, Basara I, Simsir IY, et al. Pelvis magnetic resonance imaging to diagnose Familial partial lipodystrophy. J Clin Endocrinol Metab. 2023;108:e512\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"1301_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ando.2024.05.015","volume":"85","author":"H Mosbah","year":"2024","unstructured":"Mosbah H, Vatier C, Vigouroux C. Partial lipodystrophy: clinical presentation and treatment. Ann Endocrinol (Paris). 2024;85:197\u2013200.","journal-title":"Ann Endocrinol (Paris)"},{"key":"1301_CR15","doi-asserted-by":"crossref","unstructured":"Vasandani C, Li X, Sekizkardes H, Brown RJ, Garg A. Phenotypic differences among Familial partial lipodystrophy due to LMNA or PPARG variants. J Endocr Soc. 2022;6.","DOI":"10.1210\/jendso\/bvac155"},{"key":"1301_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2019.12.002","volume":"293","author":"N Bonello-Palot","year":"2020","unstructured":"Bonello-Palot N, Laine M, Cuisset T, Ronchard T, Desgrouas C, Merono F, et al. High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome. Atherosclerosis. 2020;293:86\u201391.","journal-title":"Atherosclerosis"},{"key":"1301_CR17","doi-asserted-by":"crossref","unstructured":"Desgrouas C, Thalheim T, Cerino M, Badens C, Bonello-Palot N. Perilipin 1: a systematic review on its functions on lipid metabolism and atherosclerosis in mice and humans. Cardiovasc Res. Oxford University; 2024. pp. 237\u201348.","DOI":"10.1093\/cvr\/cvae005"},{"key":"1301_CR18","doi-asserted-by":"publisher","first-page":"E2318","DOI":"10.1210\/clinem\/dgac104","volume":"107","author":"KA Patel","year":"2022","unstructured":"Patel KA, Burman S, Laver TW, Hattersley AT, Frayling TM, Weedon MN. PLIN1 haploinsufficiency causes a favorable metabolic profile. J Clin Endocrinol Metab. 2022;107:E2318\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"1301_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ando.2024.05.017","volume":"85","author":"X Prieur","year":"2024","unstructured":"Prieur X. Generalized lipodystrophies: clinical characterization and physiopathology. Ann Endocrinol (Paris). 2024;85:195\u20136.","journal-title":"Ann Endocrinol (Paris)"},{"key":"1301_CR20","doi-asserted-by":"crossref","unstructured":"Mathur SK, Tiwari P, Gupta S, Gupta N, Nimesh S, Medicherla KM, et al. Genetics of lipodystrophy: can it help in Understanding the pathophysiology of metabolic syndrome? Biomolecules. MDPI AG; 2018.","DOI":"10.3390\/biom8030047"},{"key":"1301_CR21","doi-asserted-by":"crossref","unstructured":"Koo E, Meral R, Ozer M, Jalal Eldin A, Miller N, Rothberg A et al. MON-104 defining the contribution of weight to the extent of metabolic disease in FPLD: insights from a retrospective matched Case-Control study. J Endocr Soc. 2019;3.","DOI":"10.1210\/js.2019-MON-104"},{"key":"1301_CR22","doi-asserted-by":"crossref","unstructured":"Lima JG, Nobrega LHC, De Lima NN, Do Nascimento Santos MG, Baracho MFP, Jeronimo SMB. Clinical and laboratory data of a large series of patients with congenital generalized lipodystrophy. Diabetol Metab Syndr. 2016;8.","DOI":"10.1186\/s13098-016-0140-x"},{"key":"1301_CR23","doi-asserted-by":"crossref","unstructured":"Fourman LT, Lima JG, Simha V, Cappa M, Alyaarubi S, Montenegro R et al. A rapid action plan to improve diagnosis and management of lipodystrophy syndromes. Front Endocrinol (Lausanne). 2024;15.","DOI":"10.3389\/fendo.2024.1383318"},{"key":"1301_CR24","doi-asserted-by":"crossref","unstructured":"Akinci B, Onay H, Demir T, Ozen S, Kayserili H, Akinci G et al. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey. J Clin Endocrinol Metab [Internet]. 2016;101:2759\u201367. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27144933","DOI":"10.1210\/jc.2016-1005"},{"key":"1301_CR25","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2337\/db23-0575","volume":"73","author":"S Agrawal","year":"2024","unstructured":"Agrawal S, Luan J, Cummings BB, Weiss EJ, Wareham NJ, Khera AV. Relationship of fat mass ratio, a biomarker for lipodystrophy, with cardiometabolic traits. Diabetes. 2024;73:1099\u2013111.","journal-title":"Diabetes"},{"key":"1301_CR26","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","volume":"105","author":"C Vasandani","year":"2020","unstructured":"Vasandani C, Li X, Sekizkardes H, Adams-Huet B, Brown RJ, Garg A. Diagnostic value of anthropometric measurements for Familial partial lipodystrophy, Dunnigan variety. J Clin Endocrinol Metab. 2020;105:2132\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"1301_CR27","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2337\/dc18-0978","volume":"41","author":"R Meral","year":"2018","unstructured":"Meral R, Ryan BJ, Malandrino N, Jalal A, Neidert AH, Muniyappa R, et al. Fat shadows from DXA for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers. Diabetes Care. 2018;41:2255\u20138.","journal-title":"Diabetes Care"},{"key":"1301_CR28","doi-asserted-by":"crossref","unstructured":"Liberato CBR, Olegario NBDC, Fernandes VO, Montenegro APDR, Lima GEDCP, Batista LAA et al. Early left ventricular systolic dysfunction detected by two-dimensional speckle-tracking echocardiography in young patients with congenital generalized lipodystrophy. Diabetes Metab Syndr Obes. 2020;13.","DOI":"10.2147\/DMSO.S233667"},{"key":"1301_CR29","doi-asserted-by":"crossref","unstructured":"Rego AG, Mesquita ET, Faria CA, Rego MA, Baracho Mde F, Santos MG et al. [Cardiometabolic abnormalities in patients with Berardinelli-Seip syndrome]. Arq Bras Cardiol [Internet]. 2010;94:109\u201318. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20414534","DOI":"10.1590\/S0066-782X2010000100017"},{"key":"1301_CR30","doi-asserted-by":"crossref","unstructured":"Al Yaarubi S, Alsagheir A, Al Shidhani A, Alzelaye S, Alghazir N, Brema I et al. Analysis of disease characteristics of a large patient cohort with congenital generalized lipodystrophy from the middle East and North Africa. Orphanet J Rare Dis. 2024;19.","DOI":"10.1186\/s13023-024-03084-2"},{"key":"1301_CR31","unstructured":"Seip M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta paediatr. 1959\/11\/01. 1959;48:555\u201374."},{"key":"1301_CR32","doi-asserted-by":"crossref","unstructured":"Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. Journal of International Medical Research [Internet]. 2023;51. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605231164548","DOI":"10.1177\/03000605231164548"},{"key":"1301_CR33","doi-asserted-by":"crossref","unstructured":"Janaszak-Jasiecka A, P\u0142oska A, Wiero\u0144ska JM, Dobrucki LW, Kalinowski L. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cell Mol Biol Lett. 2023;28.","DOI":"10.1186\/s11658-023-00423-2"},{"key":"1301_CR34","doi-asserted-by":"crossref","unstructured":"Craveiro Sarmento AS, Gomes Lima J, de Souza Timoteo AR, Galv\u00e3o Ururahy MA, Antunes de Ara\u00fajo A, Carvalho Vasconcelos R et al. Changes in redox and Endoplasmic reticulum homeostasis are related to congenital generalized lipodystrophy type 2. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865.","DOI":"10.1016\/j.bbalip.2020.158610"},{"key":"1301_CR35","doi-asserted-by":"publisher","first-page":"C1410","DOI":"10.1152\/ajpcell.00698.2023","volume":"326","author":"Z Meng","year":"2024","unstructured":"Meng Z, Liu C, Xu M, Tao Y, Li H, Wang X, et al. Adipose transplantation improves metabolism and atherosclerosis but not perivascular adipose tissue abnormality or vascular dysfunction in lipodystrophic Seipin\/Apoe null mice. Am J Physiol Cell Physiol. 2024;326:C1410\u201322.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1301_CR36","doi-asserted-by":"crossref","unstructured":"Akinci G, Alyaarubi S, Patni N, Alhashmi N, Al-Shidhani A, Prodam F et al. Metabolic and other morbid complications in congenital generalized lipodystrophy type 4. Am J Med Genet A. 2024;194.","DOI":"10.1002\/ajmg.a.63533"},{"key":"1301_CR37","doi-asserted-by":"crossref","unstructured":"Guidorizzi NR, Valerio CM, Viola LF, Veras VR, Fernandes VO, Lima GE da. CP, Comprehensive analysis of morbidity and mortality patterns in Familial partial lipodystrophy patients: insights from a population study. Front Endocrinol (Lausanne). 2024;15.","DOI":"10.3389\/fendo.2024.1359211"},{"key":"1301_CR38","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/cen.14426","volume":"94","author":"AJ Eldin","year":"2021","unstructured":"Eldin AJ, Akinci B, da Rocha AM, Meral R, Simsir IY, Adiyaman SC, et al. Cardiac phenotype in Familial partial lipodystrophy. Clin Endocrinol (Oxf). 2021;94:1043\u201353.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1301_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","volume":"72","author":"B Akinci","year":"2017","unstructured":"Akinci B, Onay H, Demir T, Savas-Erdeve \u015e, Gen R, Simsir IY, et al. Clinical presentations, metabolic abnormalities and end-organ complications in patients with Familial partial lipodystrophy. Metabolism. 2017;72:109\u201319.","journal-title":"Metabolism"},{"key":"1301_CR40","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1210\/js.2019-00103","volume":"3","author":"AB Kinzer","year":"2019","unstructured":"Kinzer AB, Shamburek RD, Lightbourne M, Muniyappa R, Brown RJ. Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy. J Endocr Soc. 2019;3:1503\u201317.","journal-title":"J Endocr Soc"},{"key":"1301_CR41","doi-asserted-by":"crossref","unstructured":"Hussain I, Patni N, Garg A. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology [Internet]. 2019\/01\/01. 2019;51:202\u201312. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30595509","DOI":"10.1016\/j.pathol.2018.11.004"},{"key":"1301_CR42","doi-asserted-by":"crossref","unstructured":"Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab [Internet]. 2000\/06\/08. 2000;85:1776\u201382. Available from: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=10843151","DOI":"10.1210\/jcem.85.5.6605"},{"key":"1301_CR43","doi-asserted-by":"publisher","unstructured":"Chandalia M, Garg A, Vuitch F, Nizzi F. Postmortem findings in congenital generalized lipodystrophy. J Clin Endocrinol Metab [Internet]. 1995;80:3077\u201381. Available from: https:\/\/academic.oup.com\/jcem\/article-lookup\/doi\/https:\/\/doi.org\/10.1210\/jcem.80.10.7559900","DOI":"10.1210\/jcem.80.10.7559900"},{"key":"1301_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MD.0b013e3181e9442f","volume":"89","author":"BC Lupsa","year":"2010","unstructured":"Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: A clinical assessment. Medicine. 2010;89:245\u201350.","journal-title":"Medicine"},{"key":"1301_CR45","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Pombo A, S\u00e1nchez-Iglesias S, Castro-Pais AI, Ginzo-Villamayor MJ, Cobelo-G\u00f3mez S, Prado-Mora\u00f1a T et al. Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain. Front Endocrinol (Lausanne). 2023;14.","DOI":"10.3389\/fendo.2023.1250203"},{"key":"1301_CR46","doi-asserted-by":"crossref","unstructured":"Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation [Internet]. 2001\/05\/23. 2001;103:2225\u20139. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11342468","DOI":"10.1161\/01.CIR.103.18.2225"},{"key":"1301_CR47","doi-asserted-by":"publisher","unstructured":"Agarwal AK, Simha V, Oral EA, Moran SA, Gorden P, O\u2019Rahilly S. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab [Internet]. 2003\/10\/15. 2003;88:4840\u20137. Available from: https:\/\/doi.org\/10.1210\/jc.2003-030855","DOI":"10.1210\/jc.2003-030855"},{"key":"1301_CR48","unstructured":"Ponte CMM, Fernandes VO, Gurgel MHC, Vasconcelos I, Karbage L, Liberato CBR et al. Early commitment of cardiovascular autonomic modulation in Brazilian patients with congenital generalized lipodystrophy. BMC Cardiovasc Disord [Internet]. 2018\/01\/14. 2018;18:6. Available from: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=29329523"},{"key":"1301_CR49","doi-asserted-by":"crossref","unstructured":"Brown RJ, Akinci B, Yosef M, Phillips H, Khalatbari S, Sorkina E et al. Lipodystrophy severity score to assess disease burden in lipodystrophy. J Clin Endocrinol Metab. 2025.","DOI":"10.1210\/clinem\/dgaf103"},{"key":"1301_CR50","doi-asserted-by":"crossref","unstructured":"Cecchetti C, Belardinelli E, Dionese P, Teglia R, Fazzeri R, D\u2019 Apice MR et al. Is it possible to achieve an acceptable disease control by dietary therapy alone in Berardinelli Seip type 1? Experience from a case report. Front Endocrinol (Lausanne). 2023;14.","DOI":"10.3389\/fendo.2023.1190363"},{"key":"1301_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000533992","volume":"17","author":"MC Foss-Freitas","year":"2024","unstructured":"Foss-Freitas MC, Besci \u00d6, Meral R, Neidert A, Chenevert TL, Oral EA, et al. A Very-Low-Calorie diet can cause remission of diabetes mellitus and hypertriglyceridemia in Familial partial lipodystrophy. Obes Facts. 2024;17:103\u20138.","journal-title":"Obes Facts"},{"key":"1301_CR52","doi-asserted-by":"crossref","unstructured":"Chakraborty S, Roy S, Das D, Chatterjee S, Sahana PK, Mukhopadhyay S. A very low carbohydrate diet improved metabolic profile in congenital generalized lipodystrophy type 4. Endocrinol Diabetes Metab Case Rep. 2025;2025.","DOI":"10.1530\/EDM-24-0063"},{"key":"1301_CR53","doi-asserted-by":"crossref","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab [Internet]. 2016\/10\/07. 2016;101:4500\u201311. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27710244","DOI":"10.1210\/jc.2016-2466"},{"key":"1301_CR54","doi-asserted-by":"crossref","unstructured":"Hummadi A, Yafei S, Mutawwam DA, Abutaleb R, Solan Y, Khawaji A et al. Genomic and bioinformatics analysis of Familial partial lipodystrophy type 3 identified in a patient with novel PPAR\u03b3 mutation and robust response to Pioglitazone. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms252212060"},{"key":"1301_CR55","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2337\/dc23-1614","volume":"47","author":"MC Foss-Freitas","year":"2024","unstructured":"Foss-Freitas MC, Imam S, Neidert A, Gomes AD, Broome DT, Oral EA. Efficacy and safety of glucagonlike peptide 1 agonists in a retrospective study of patients with Familial partial lipodystrophy. Diabetes Care. 2024;47:653\u20139.","journal-title":"Diabetes Care"},{"key":"1301_CR56","doi-asserted-by":"publisher","unstructured":"Ten S, Bhangoo A, Buettner C. Tirzepatide for Congenital Generalized Lipodystrophy. New England Journal of Medicine [Internet]. 2025;392:717\u20139. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMc2413871","DOI":"10.1056\/NEJMc2413871"},{"key":"1301_CR57","doi-asserted-by":"publisher","unstructured":"Meral R, Celik Guler M, Kaba D, Prativadi J, Frontera ED, Foss-Freitas MC et al. Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option? Diabetes Care [Internet]. 2025; Available from: https:\/\/diabetesjournals.org\/care\/article\/doi\/https:\/\/doi.org\/10.2337\/dc24-2408\/157974\/Metabolic-Improvements-With-Tirzepatide-in","DOI":"10.2337\/dc24-2408\/157974\/Metabolic-Improvements-With-Tirzepatide-in"},{"key":"1301_CR58","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7326\/L16-0372","volume":"166","author":"Y Kawana","year":"2017","unstructured":"Kawana Y, Imai J, Sawada S, Yamada T, Katagiri H. Sodium\u2013Glucose cotransporter 2 inhibitor improves complications of lipodystrophy: A case report. Ann Intern Med. 2017;166:450.","journal-title":"Ann Intern Med"},{"key":"1301_CR59","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LStL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with Familial partial lipodystrophy: results of the BROADEN study. J Clin Lipidol. 2022;16:833\u201349.","journal-title":"J Clin Lipidol"},{"key":"1301_CR60","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ando.2024.05.022","volume":"85","author":"C Vigouroux","year":"2024","unstructured":"Vigouroux C, Mosbah H, Vatier C. Leptin replacement therapy in the management of lipodystrophy syndromes. Ann Endocrinol (Paris). 2024;85:201\u20134.","journal-title":"Ann Endocrinol (Paris)"},{"key":"1301_CR61","doi-asserted-by":"crossref","unstructured":"Calcaterra V, Magenes VC, Rossi V, Fabiano V, Mameli C, Zuccotti G. Lipodystrophies in non-insulin-dependent children: treatment options and results from Recombinant human leptin therapy. Pharmacol Res. 2023;187.","DOI":"10.1016\/j.phrs.2022.106629"},{"key":"1301_CR62","doi-asserted-by":"publisher","first-page":"E4327","DOI":"10.1210\/clinem\/dgab499","volume":"106","author":"M Nguyen","year":"2021","unstructured":"Nguyen M, Le, Sachdev V, Burklow TR, Li W, Startzell M, Auh S, et al. Leptin attenuates cardiac hypertrophy in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2021;106:E4327\u201339.","journal-title":"J Clin Endocrinol Metab"},{"key":"1301_CR63","doi-asserted-by":"crossref","unstructured":"Gewitz A, Mendell J, Wang Y, Harris C, Olenchock BA, Podgrabinska S et al. Pharmacokinetics and pharmacodynamics of Mibavademab (a leptin receptor agonist): results from a first-in\u2010human phase I study. Clin Transl Sci. 2024;17.","DOI":"10.1111\/cts.13762"},{"key":"1301_CR64","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.omtm.2022.09.014","volume":"27","author":"N Sommer","year":"2022","unstructured":"Sommer N, Roumane A, Han W, Delibegovi\u0107 M, Rochford JJ, Mcilroy GD. Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy. Mol Ther Methods Clin Dev. 2022;27:206\u201316.","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01301-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01301-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01301-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:37:13Z","timestamp":1747121833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01301-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01301-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"27 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal subjects were used in this study. All studies with human subjects are published and followed ethical, institutional standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"55"}}